Table 1.

Approved classes of antivirals for influenza virus.

Drug	Class	Target Action	Brand Name	Virus Type	Administration Route	Approval Agency	Approval Year
Amanadine	M2 ion channel blockers	Blocks the viral uncoating and entry into the host cell	Symmetrel	A	Oral	No longer	1963
Rimantadine	M2 ion channel blockers	Blocks the viral uncoating and entry into the host cell	Flumadine	A	Oral	No longer	1969
Zanamivir	NA inhibitor	Blocks viral NA activity	Relenza	A & B	Nasal or Oral	FDA	1993
Oseltamivir	NA inhibitor	Blocks viral NA activity	Tamiflu	A & B	Oral	FDA	1998
Peramivir	NA inhibitor	Blocks viral NA activity	Rapivab, Peramiflu	A & B	I.M, I. V	FDA	2000
Laninamivir	NA inhibitor	Blocks viral NA activity	Inavir	A & B	Nasal	Japan	2010
Favipiravir	RNA polymerase inhibitor	Inhibits viral RNA-dependent RNA polymerase substrate	Avigan	A & B	Oral	Japan, China	2002
Baloxavir marboxil	Polymerase acidic Endonuclease inhibitor	Inhibits the activity of cap-dependent endonuclease	Xofluza	A & B	Oral	FDA	2018

FDA—Food and Drug Administration, I.M—Intramuscular, I.V—Intravenous